EA200100302A1 - Способы и композиции для протективной и терапевтической генетической иммунизации - Google Patents
Способы и композиции для протективной и терапевтической генетической иммунизацииInfo
- Publication number
- EA200100302A1 EA200100302A1 EA200100302A EA200100302A EA200100302A1 EA 200100302 A1 EA200100302 A1 EA 200100302A1 EA 200100302 A EA200100302 A EA 200100302A EA 200100302 A EA200100302 A EA 200100302A EA 200100302 A1 EA200100302 A1 EA 200100302A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- cells
- viral particles
- lymphoid organs
- present
- transduction
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 230000001681 protective effect Effects 0.000 title abstract 3
- 230000001225 therapeutic effect Effects 0.000 title abstract 3
- 230000002068 genetic effect Effects 0.000 title abstract 2
- 238000002649 immunization Methods 0.000 title abstract 2
- 230000003053 immunization Effects 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 210000004027 cell Anatomy 0.000 abstract 5
- 230000002238 attenuated effect Effects 0.000 abstract 4
- 210000005210 lymphoid organ Anatomy 0.000 abstract 4
- 239000002245 particle Substances 0.000 abstract 4
- 230000003612 virological effect Effects 0.000 abstract 4
- 241001465754 Metazoa Species 0.000 abstract 3
- 230000026683 transduction Effects 0.000 abstract 3
- 238000010361 transduction Methods 0.000 abstract 3
- 241000700605 Viruses Species 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 241000282412 Homo Species 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 230000007416 antiviral immune response Effects 0.000 abstract 1
- 230000005860 defense response to virus Effects 0.000 abstract 1
- 210000004443 dendritic cell Anatomy 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 230000036039 immunity Effects 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4634—Antigenic peptides; polypeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16061—Methods of inactivation or attenuation
- C12N2740/16062—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hematology (AREA)
- AIDS & HIV (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Описаны и заявлены способы и композиции для продуцирования протективного и терапевтического иммунитета у человека и животных путем генетической иммунизации. Настоящее изобретение обеспечивает как безопасность, так и эффективность лечения вирусных инфекций и связанных с ними заболеваний. Способы настоящего изобретения предусматривают трансдукцию клеток с использованием конструкции, которая направляет экспрессию аттенуированного вируса, не способного вызывать заболевание, например являющегося не компетентным по репликации. Обеспечиваемая настоящим изобретением повышенная эффективность в вырабатывании антивирусного иммунного ответа обусловлена отчасти уникальным способом «транспортировки» аттенуированных вирусных частиц в организм хозяина человека или животного. В частности, аттенуированные непатогенные вирусные частицы настоящего изобретения, которые продуцируют терапевтический или протективный иммунный ответ, экспрессируются клетками в лимфоидных органах так, что высвобождение вирусных частиц происходит в той области организма человека или животного, где антивирусный ответ обычно индуцируется клетками иммунной системы. Высвобождение вирусных частиц в лимфоидных органах достигается путем трансдукции клеток-хозяев в лимфоидных органах (или клеток, которые мигрируют предпочтительно в лимфоидные органы) с помощью генной конструкции, которая обеспечивает экспрессию аттенуированного вируса. Как подробно описано в заявке, особенно предпочтительной является трансдукция дендритных клеток.Международная заявка была опубликована вместе с отчетом о международном поиске.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60462796A | 1996-02-21 | 1996-02-21 | |
PCT/US1997/002933 WO1997031119A1 (en) | 1996-02-21 | 1997-02-20 | Methods and compositions for protective and therapeutic genetic immunization |
Publications (2)
Publication Number | Publication Date |
---|---|
EA200100302A1 true EA200100302A1 (ru) | 2001-10-22 |
EA003554B1 EA003554B1 (ru) | 2003-06-26 |
Family
ID=24420371
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA199800746A EA002020B1 (ru) | 1996-02-21 | 1997-02-20 | Способ генерации противовирусного иммунного ответа у человека или животного |
EA200100302A EA003554B1 (ru) | 1996-02-21 | 1997-02-20 | Фармацевтическая композиция для генерации противовирусного иммунного ответа у человека и животного |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA199800746A EA002020B1 (ru) | 1996-02-21 | 1997-02-20 | Способ генерации противовирусного иммунного ответа у человека или животного |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP0882134B8 (ru) |
JP (1) | JP2000517290A (ru) |
AP (1) | AP964A (ru) |
AT (1) | ATE429505T1 (ru) |
AU (1) | AU726623B2 (ru) |
CA (1) | CA2246359A1 (ru) |
DE (1) | DE69739372D1 (ru) |
EA (2) | EA002020B1 (ru) |
ES (1) | ES2324745T3 (ru) |
NZ (1) | NZ331369A (ru) |
OA (1) | OA10842A (ru) |
WO (1) | WO1997031119A1 (ru) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU3210997A (en) * | 1996-05-24 | 1997-12-09 | University Of Maryland At Baltimore | Dna vaccines for eliciting a mucosal immune response |
US20060002949A1 (en) | 1996-11-14 | 2006-01-05 | Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. | Transcutaneous immunization without heterologous adjuvant |
NZ503334A (en) * | 1997-09-15 | 2002-05-31 | Genetic Immunity Llc | A gene delivering complex having a vector with a specific affinity for a foreign genetic material and a second site having a specific affinity for a receptor on an antigen presenting cell |
EP1037669A4 (en) * | 1997-12-12 | 2003-04-02 | Cell Genesys Inc | THERAPEUTIC USE OF LENTIVIRAL VECTORS |
WO1999047146A1 (en) * | 1998-03-17 | 1999-09-23 | Julianna Lisziwiewicz | Anti-hiv combination comprising hydroxyurea, ddi, and a protease inhibitor |
US6461616B1 (en) * | 2000-09-09 | 2002-10-08 | Akzo Nobel Nv | EIAV p26 deletion vaccine and diagnostic |
US20070025958A1 (en) | 2000-10-27 | 2007-02-01 | Hadden John W | Vaccine immunotherapy |
EP1337149A4 (en) | 2000-10-27 | 2005-10-12 | Irx Therapeutics Inc | VACCINE IMMUNOTHERAPY FOR IMMUNE-PATIENT PATIENTS |
US7628980B2 (en) | 2000-11-23 | 2009-12-08 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
US7445924B2 (en) | 2000-11-23 | 2008-11-04 | Bavarian Nordic A/S | Modified Vaccinia Ankara virus variant and cultivation method |
US7097842B2 (en) | 2000-11-23 | 2006-08-29 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
NZ524661A (en) | 2000-11-23 | 2005-03-24 | Bavarian Nordic As | Modified vaccinia ankara virus variant |
AU2002356690B2 (en) | 2001-12-04 | 2008-07-24 | Bavarian Nordic A/S | Flavivirus NS1 subunit vaccine |
PT1420822E (pt) | 2002-04-19 | 2007-09-04 | Bavarian Nordic As | Vírus vacínia modificado ancara para a vacinação de neonatais |
CA2494379C (en) | 2002-09-05 | 2012-11-06 | Bavarian Nordic A/S | Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions |
WO2004065575A2 (en) * | 2003-01-15 | 2004-08-05 | Research Institute For Genetic And Human Therapy (Right) | Dna compositon and uses thereof |
FR2872170B1 (fr) * | 2004-06-25 | 2006-11-10 | Centre Nat Rech Scient Cnrse | Lentivirus non interactif et non replicatif, preparation et utilisations |
EP1797189A4 (en) * | 2004-09-02 | 2010-05-19 | Qun Chen | ENCAPSIDATION SYSTEM FOR THE PRODUCTION OF RECOMBINANT VIRUSELY PARTICLES |
GB0526211D0 (en) * | 2005-12-22 | 2006-02-01 | Oxford Biomedica Ltd | Viral vectors |
EP2150618B1 (en) | 2007-05-04 | 2017-10-11 | University Health Network | Il-12 immunotherapy for cancer |
WO2009070639A1 (en) | 2007-11-28 | 2009-06-04 | Irx Therapeutics, Inc. | Method of increasing immunological effect |
WO2010009465A2 (en) * | 2008-07-18 | 2010-01-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Htlv-ii vector and methods of use |
WO2010132867A1 (en) | 2009-05-15 | 2010-11-18 | Irx Therapeutics, Inc. | Vaccine immunotherapy |
AU2010328197B2 (en) | 2009-12-08 | 2015-07-16 | Irx Therapeutics, Inc. | Method of reversing immune suppression of Langerhans cells |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5342774A (en) * | 1991-05-23 | 1994-08-30 | Ludwig Institute For Cancer Research | Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1 |
WO1994024267A1 (en) * | 1993-04-20 | 1994-10-27 | Robinson, William, S. | Methods and materials for treatment of individuals infected with intracellular infectious agents |
US6080408A (en) * | 1994-08-22 | 2000-06-27 | Connaught Laboratories Limited | Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles |
-
1997
- 1997-02-20 EP EP97906764A patent/EP0882134B8/en not_active Expired - Lifetime
- 1997-02-20 WO PCT/US1997/002933 patent/WO1997031119A1/en active Application Filing
- 1997-02-20 AU AU21369/97A patent/AU726623B2/en not_active Ceased
- 1997-02-20 EA EA199800746A patent/EA002020B1/ru not_active IP Right Cessation
- 1997-02-20 NZ NZ331369A patent/NZ331369A/en not_active IP Right Cessation
- 1997-02-20 ES ES97906764T patent/ES2324745T3/es not_active Expired - Lifetime
- 1997-02-20 EA EA200100302A patent/EA003554B1/ru not_active IP Right Cessation
- 1997-02-20 AT AT97906764T patent/ATE429505T1/de not_active IP Right Cessation
- 1997-02-20 JP JP09530399A patent/JP2000517290A/ja not_active Ceased
- 1997-02-20 CA CA002246359A patent/CA2246359A1/en not_active Abandoned
- 1997-02-20 AP APAP/P/1998/001320A patent/AP964A/en active
- 1997-02-20 DE DE69739372T patent/DE69739372D1/de not_active Expired - Lifetime
-
1998
- 1998-08-18 OA OA9800147A patent/OA10842A/en unknown
Also Published As
Publication number | Publication date |
---|---|
AP9801320A0 (en) | 1998-09-30 |
EA003554B1 (ru) | 2003-06-26 |
DE69739372D1 (de) | 2009-06-04 |
WO1997031119A1 (en) | 1997-08-28 |
JP2000517290A (ja) | 2000-12-26 |
ES2324745T3 (es) | 2009-08-13 |
EP0882134A1 (en) | 1998-12-09 |
NZ331369A (en) | 2001-04-27 |
CA2246359A1 (en) | 1997-08-28 |
EP0882134B8 (en) | 2009-09-02 |
ATE429505T1 (de) | 2009-05-15 |
EA199800746A1 (ru) | 1999-02-25 |
EP0882134B1 (en) | 2009-04-22 |
EA002020B1 (ru) | 2001-12-24 |
AU726623B2 (en) | 2000-11-16 |
AP964A (en) | 2001-05-11 |
OA10842A (en) | 2001-08-14 |
AU2136997A (en) | 1997-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200100302A1 (ru) | Способы и композиции для протективной и терапевтической генетической иммунизации | |
DE69332518D1 (de) | Unterdrückung von autoimmunkrankheiten durch antigene in wartestellung | |
MX9203458A (es) | Segmentos inmunogenicos que contienen glicoproteinas quimericas de las glicoproteinas de virus sincitial respiratorio humano. | |
DK1252323T3 (da) | Virus-stammer til den onkolytiske behandling af cancer | |
ATE319474T1 (de) | Behandlung von autoimmunkrankheiten durch orale verabreichung von autoantigenen | |
DE68927348D1 (de) | Künstlicher impfstoff gegen aids-virus | |
BR9610590A (pt) | Glicoproteìnas e vacinas de vìrus parainfluenza | |
ATE101200T1 (de) | Impfstoffe gegen menschliche respiratorische viren. | |
LT2003009A (en) | Use of strains of the parapox ovis virus for producting antiviral pharmaceuticals and anticancer pharmaceuticals | |
Van Campen | Influenza A virus replication is inhibited by tumor necrosis factor-α in vitro | |
DE69833876D1 (de) | Zusammensetzungen und methoden zur zielgerichteten abgabe von biologisch aktivenfaktoren | |
EP0188590A1 (en) | Therapeutic preparations for treatment of certain viral and other diseases and the preparation of the same | |
EA199800526A1 (ru) | Производные бензимидазола и их применение для лечения вирусных инфекций | |
BR0109928A (pt) | Uso de um herpes vìrus atenuado, e, método para estimular uma resposta imune em um indivìduo humano ou animal, ou para tratar ou prevenir uma infecção patogênica ou câncer em um indivìduo humano ou animal | |
CY1107784T1 (el) | Πρωτεϊνη συντηξης g του ihnv για διεγερση του ανοσοποιητικου συστηματος | |
DE69633919D1 (de) | Mehrzweckvakzine gegen umhüllte viren | |
HUP9900945A2 (hu) | Nukleozidanalógok herpes simplex vírus fertőzések kombinációs terápiájában | |
EA199901061A1 (ru) | Новые соли врс-пептидов с органопротективной активностью, способ их получения и их использование в терапии | |
Nuñez-Ortiz et al. | Immunostimulant properties of full-length and truncated Marinobacter algicola flagellins, and their effects against viral hemorrhagic septicemia virus (VHSV) in trout | |
DE60024259D1 (de) | Trennung eines humanen retrovirus | |
Berry | Towards a universal influenza virus vaccine eliciting broadly neutralising haemagglutinin antibodies | |
FR2792639B1 (fr) | Nouveaux immunogenes anti-vih (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida | |
EA202100185A2 (ru) | Вакцина и способ повышения иммуногенности и специфической активности средств профилактики инфекций | |
EA199700353A1 (ru) | Композиция и способ для определения приобретенного синдрома иммунодефицита, способ приготовления названной композиции | |
NO982151L (no) | Hemoregulatoriske forbindelser |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |